CN112239744A - 一种能够促进牙髓干细胞成骨转化的干扰rna及其应用 - Google Patents

一种能够促进牙髓干细胞成骨转化的干扰rna及其应用 Download PDF

Info

Publication number
CN112239744A
CN112239744A CN202011121438.7A CN202011121438A CN112239744A CN 112239744 A CN112239744 A CN 112239744A CN 202011121438 A CN202011121438 A CN 202011121438A CN 112239744 A CN112239744 A CN 112239744A
Authority
CN
China
Prior art keywords
sirna
dental pulp
stem cells
pulp stem
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202011121438.7A
Other languages
English (en)
Other versions
CN112239744B (zh
Inventor
刘金凤
高杨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qingdao Situo Xinyuan Cell Medicine Co ltd
Qingdao Women and Childrens Hospital
Original Assignee
Qingdao Women and Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qingdao Women and Childrens Hospital filed Critical Qingdao Women and Childrens Hospital
Priority to CN202011121438.7A priority Critical patent/CN112239744B/zh
Publication of CN112239744A publication Critical patent/CN112239744A/zh
Application granted granted Critical
Publication of CN112239744B publication Critical patent/CN112239744B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0654Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662Stem cells
    • C12N5/0664Dental pulp stem cells, Dental follicle stem cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/113Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及牙髓干细胞技术领域,尤其涉及一种能够促进牙髓干细胞成骨转化的干扰RNA及其应用。本发明所提供的干扰RNA为siRNA,所述siRNA的正义链序列如SEQ ID NO.4所示,所示siRNA的反义链序列如SEQ ID NO.5所示,本发明所提供的siRNA能够有效的抑制LOC107985830的表达来促进牙髓干细胞的成骨转化,因此可将其用于制备牙髓干细胞成骨转化促进剂。

Description

一种能够促进牙髓干细胞成骨转化的干扰RNA及其应用
技术领域
本发明涉及牙髓干细胞技术领域,尤其涉及一种能够促进牙髓干细胞成骨转化的干扰RNA及其应用。
背景技术
临床上由于牙髓的创伤或者感染引起的牙髓炎或者根尖周炎的传统治疗方法通常采用根管治疗的方法来治疗。然而传统的根管治疗方法存在一定的不足。因此,研究人员基于组织工程原料,提出了牙髓再生治疗。但是作为牙髓再生种子细胞的牙髓干细胞具有多种不同的转化方向,如何促进牙髓干细胞的成骨转化去进一步生产牙齿是急需解决的问题。
哺乳动物基因组中,超过90%的基因均转录为非编码RNA,在最开始的研究中,研究人员将非编码RNA认定为垃圾RNA。然而,随着大规模基因组测序的完成,研究人员发现非编码RNA在生理过程中发挥关键性作用。长链非编码RNA是非编码RNA家族中的重要成员,其占人体内全部非编码RNA的大部分,lncRNA的核苷酸序列长度超过200个核苷酸。lncRNA在人体组织内的表达非常广泛,具有较强的特异性。尽管lncRNA不能编码蛋白质,但是lncRNA几乎参与基因表达调控的每一个层面,涉及转录调控,染色质重塑,细胞内物质运输等多种生物学进程。
目前,长链非编码RNA LOC107985830在牙髓干细胞中的作用尚未见报道。
发明内容
本发明的目的在于提供一种能够有效的促进牙髓干细胞成骨转化的促进剂。
为实现上述目的,本发明提供了如下技术方案:
本发明提供了LOC107985830功能性表达的抑制剂在制备用于促进牙髓干细胞成骨转化的促进剂中的用途。
优选地,所述LOC107985830的转录本序列为XR_001739224.1。
优选地,所述抑制剂选自LOC107985830的shRNA或siRNA。
优选地,所述抑制剂为LOC107985830的siRNA,所述siRNA的正义链为SEQ ID NO.4所示,所述siRNA的反义链为SEQ ID NO.5所述。
此外,本发明提供了一种促进牙髓干细胞成骨转化的促进剂,所述促进剂为抑制LOC107985830功能性表达的抑制剂,所述抑制剂为siRNA,所述siRNA的正义链为SEQ IDNO.4所示,所述siRNA的反义链为SEQ ID NO.5所示.
此外,本发明提供了一种LOC107985830的基因抑制剂,所述抑制剂为LOC107985830的siRNA,所述siRNA的正义链为SEQ ID NO.4所示,所示siRNA的反义链为SEQ ID NO.5所示,所述siRNA能够促进牙髓干细胞成骨。
此外,本发明提供了一种长链非编码RNA,其特征在于,所述长链非编码RNA为LOC107985830,所述LOC107985830的转录本序列为XR_001739224.1,所述LOC107985830的抑制剂能够促进牙髓干细胞成骨。
本发明的有益效果在于:
本发明首次证明了通过siRNA抑制LOC107985830能够有效的促进牙髓干细胞的ALP活性,细胞钙化以及成骨转化相关基因RUNX2和OCN的蛋白表达,因此,LOC107985830的siRNA能够有效的牙髓干细胞的成骨转化,从而为进一步使牙髓干细胞通过成骨转化分化为牙本质去修复牙齿提供基础。
附图说明
图1 siLOC107985830-1,siLOC107985830-2,siLOC107985830-3对于LOC107985830的干扰效果。
图2 抑制LOC107985830对于ALP活性的影响。
图3 抑制LOC107985830对于细胞钙化的影响。
图4 抑制LOC107985830对于成骨转化相关蛋白RUNX2和OCN的影响。
具体实施方式
实施例1
(1)将本院收集的8-12岁的牙面形态完整且无龋的牙齿浸入到加有双抗的无菌PBS中进行冲洗,同时将牙根部和颈部所附着的牙周膜等软组织全部去除;
(2)沿着牙齿长轴将牙齿纵行劈开,并且在无菌条件下,使用无菌镊子将牙髓组织取出,置于无菌EP管中;
(3)使用PBS洗涤3次后,加入500μl PBS并用剪刀将牙髓组织剪碎,将EP管放入离心机中,1500rpm/min离心3分钟,保留沉淀,去除上清;
(4)加入I型胶原酶,置于细胞恒温培养箱中,37℃消化60min;
(5)加入适量的含10% FBS的完全培养基终止消化,1500rpm/min离心3min,弃去上清,将组织块均匀铺在培养瓶底部,加入含有10%FBS的完全培养基,放于细胞恒温培养箱中,每2-3天更换一次培养基,流式细胞仪鉴定得到牙髓干细胞。
实施例2
1.转染siRNA
(1)设计LOC107985830的siRNA
表1 siRNA序列设计表
名称 序列(5’-3’)
siLOC107985830-1 CCUACUAUGUACUCAAUAAGU(SEQ ID NO.2)
UUAUUGAGUACAUAGUAGGUG(SEQ ID NO.3)
siLOC107985830-2 CAGUGGAAGUGAUUACUAAGA(SEQ ID NO.4)
UUAGUAAUCACUUCCACUGGA(SEQ ID NO.5)
siLOC107985830-3 GCACCUACUAUGUACUCAAUA(SEQ ID NO.6)
UUGAGUACAUAGUAGGUGCCA(SEQ ID NO.7)
(2)将牙髓干细胞接种于6孔板中,培养过夜后,弃去培养基进行转染,转染分组为空白对照组,si-NC组,siLOC107985830-1组,siLOC107985830-2组和siLOC107985830-3组,每组设置3个重复。
(3)转染48h后,提取RNA。
2.提取RNA
(1)在每组细胞中加入1ml Trizol,使用移液器吹打细胞并且收集细胞至2ml EP管中,冰上放置10min;
(2)将EP管置于离心机中,12000rpm离心5min,将上清转移至新的EP管中;
(3)加入200ul氯仿,混匀后,冰上放置15min,置于离心机中,12000rpm离心5min;
(4)小心的吸取上清至新的EP管中,加入等体积的预冷异丙醇,冰上放置10min;
(5)置于离心机中,12000转离心10min,弃去上清,加入1ml 75%乙醇(DEPC水配置)溶解沉淀,置于离心机中7500转,4℃,离心5min,去除上清,室温干燥,加入DEPC水溶解沉淀。
3.逆转录获取cDNA
反应体系:总RNA 0.5ug,PrimeScript TM RT MasterMix 2ul,ddH2O up to 10ul。
反应条件:37℃ 15min;85℃ 5s;4℃ 保存。
4.荧光定量PCR
(1)引物序列
基因名称 引物序列 产物大小
LOC107985830 AGAACCACAGACAAGGGCAC(SEQ ID NO.8) 128
ATCTCCCTGTTCATGCCTGC(SEQ ID NO.9)
GAPDH TCTCTGCTCCTCCTGTTCGA(SEQ ID NO.10) 122
GCGCCCAATACGACCAAATC(SEQ ID NO.11)
(2)反应体系: SYBR Premix EX Taq 5ul; PCR forward primer 0.5ul;PCR reverseprimer 0.5ul;cDNA 1ul;ddH2O 3ul。
(3)反应条件,95℃ 5min;95℃ 10s,60℃ 30s, 40个循环。
实验结果如图1所示,从图中可以看出,siNC组的相对表达量为0.975±0.020(P=0.5326,差异无统计学意义),si LOC10798583-1组的相对表达量为0.241±0.061(P=0.0004,差异具有统计学意义),si LOC10798583-2组的相对表达量为0.145±0.034(P<0.0001,差异具有统计学意义),si LOC10798583-3组的相对表达量为0.173±0.031(P<0.0001,差异具有统计学意义)。综合上述结果可以看出,si LOC10798583-2的抑制效果最优,因此,下文所述si LOC10798583均指si LOC10798583-2。
实施例2
(1)将牙髓干细胞接种于96孔板中,每孔2000个细胞,分别转染siNC和siLOC10798583,每组设置3个重复;
(2)72h后,使用CCK-8试剂检测牙髓干细胞的OD值。
实验结果表明,siNC组的OD值为0.568±0.008,si LOC10798583组的OD值为0.637±0.053(P值为0.2657,差异不具有统计学意义),因此,si LOC10798583对于牙髓干细胞的增殖没有显著的影响。
实施例3 ALP染色
(1)将牙髓干细胞接种于6孔板中,分别转染siNC和siLOC107985830,转染后进行成骨诱导;
(2)成骨诱导14天后弃去培养基,使用PBS漂洗3次,每次3min;
(3)加入多聚甲醛进行固定,30min后,弃去固定液,加入PBS漂洗3次,每次3min;
(4)按照ALP染色试剂盒说明书配置染色液,避光染色30min,弃去染色液,PBS漂洗去除剩余染色液,倒置显微镜下观察染色情况。
实验结果如图2所示,从图中可以看出,相较于siNC组,si LOC107985830组的ALP活性显著升高,说明抑制LOC107985830能够促进牙髓干细胞ALP活性。
实施例4 茜素红染色
(1)将牙髓干细胞接种于6孔板中,分别转染siNC和siLOC10798583,转染后进行成骨诱导;
(2)成骨诱导21天后,弃去培养基,使用PBS漂洗3次,每次3min;
(3)加入多聚甲醛进行固定,30min,弃去固定液,加入PBS漂洗3次,每次3min;
(4)加入茜素红染色10min,弃去染色液,PBS漂洗去除剩余染色液,倒置显微镜下观察染色情况。
实验结果如图3所示,从图中可以看出,相较于siNC组,si LOC107985830组的钙化水平明显升高,说明抑制LOC107985830能够促进牙髓干细胞钙化。
实施例5
Western Blot检测蛋白的表达水平
1.蛋白样品制备
(1)将牙髓干细胞接种于6孔板中,分为siNC和siLOC107985830组进行转染,每组设置3个重复;
(2)成骨转化14天后,弃去细胞培养基,PBS洗涤3次,每孔加入150ul细胞裂解液,冰上裂解30min;
(3)将细胞刮下并转移至1.5ml EP管中,使用超声波细胞破碎仪破碎细胞。
(4)4℃,12000rpm条件下,离心20min,取上清至新的EP管中;
(5)根据试剂盒说明书,使用BCA法检测蛋白浓度,加入5×蛋白上样缓冲液使各组蛋白样品的浓度保持一致。
2.SDS-PAGE蛋白电泳和电转
(1)配置10%下层胶和5%上层胶,组装好电泳装置,开始电泳,上层浓缩胶恒压60V,30min,下层分离胶恒压120V,60min,当溴酚蓝条带移至距离分离胶底部约1cm时停止电泳;
(2)将胶置于转膜夹中,按照“三明治”模型制作转膜夹,过程中需要排除所有的气泡;
(3)安装好转膜装置,并置于冰盒内,倒入转膜液,恒流250mA,90min完成转膜;
(4)电转结束后,将PVDF膜取出置于5%的脱脂奶粉中,置于摇床上封闭1h;
(5)根据相应的蛋白大小,裁剪PVDF膜,并孵育RUNX2,OCN和β-actin一抗,4℃摇床孵育过夜;
(6)吸取一抗,PBS洗膜三次,每次5min,孵育二抗,室温1.5h;
(7)弃去二抗,PBS洗膜三次,每次5min,进行显影曝光。
实验结果如图4所示,从图中可以看出,相较于对照组,siLOC107985830组RUNX2和OCN的蛋白表达明显升高,说明抑制LOC107985830能够促进牙髓干细胞中RUNX2和OCN的表达。
综上所述,LOC107985830基因抑制剂能够促进牙髓干细胞的ALP活性,细胞钙化和RUNX2和OCN蛋白表达,说明LOC107985830基因抑制剂能够促进牙髓干细胞的成骨转化。
序列表
<110> 青岛市妇女儿童医院(青岛市妇幼保健院、青岛市残疾儿童医疗康复中心、青岛市新生儿疾病筛查中心)
<120> 一种能够促进牙髓干细胞成骨转化的干扰RNA及其应用
<160> 11
<170> SIPOSequenceListing 1.0
<210> 1
<211> 2089
<212> DNA
<213> 人源(Human)
<400> 1
actgcatgct actctctaga gattgtctct caactgacct agaacttcca tagccatctg 60
atcaccaaga ccgcctctga gaggaaagtt ctgagagtct caccttgctc gcatcaaaac 120
agttcctatt tatccttttt cctggatctg tgatattctg gactgtttct gtgttcagtt 180
gtggccaagt gttacagata tacctctatt ttccacaaga acagcaagca aaagagaaga 240
cagggaggca ctcagaggat ggggattctc caaaggtgaa atgcaagctt aagcagttta 300
aatgtgttga tttcaaatgg gatatgagca gcaactgcaa attataaatc atcctggtta 360
gcctactgag atcagtgagg agaagagaat gggaggatca gaacacaaat gaagtcactg 420
attacttggt tgcagccaag atgcaaaaag gaataagatg tgcttctctg ctcagaaaat 480
tcatagtcca ttgggagaat ggggtcttcc tggatcattt cagaacaacg tggaaaacaa 540
tgcaattaaa gaatgtgtgt acatagtttc atagaaccac agacaagggc acccagccta 600
tctggggtgg gtgcagaata cagaatttga aaattatcca gtggaagtga ttactaagat 660
gactcaaaaa caggactgac gcaggcatga acagggagat atgagcattc tggatggtat 720
tgcatatgga gggagaaatt ctactttgga acactgacgt caaggccagt tgggtgagag 780
atggggttgg ggcagtcatc aagtgccaga ccacacgagg atgaaatgcc ttgttaaggc 840
atctggcctt taccttgttg gcagaaggaa accattgctg agtcttaaat agtagaatga 900
catggtcagg tatgcctttc agataactct ctgacatggc cttgtagaaa attgattgga 960
gaagacaaga agatgacagg agggaatgag ccatagaaag gcagatttcc ttggaagaaa 1020
gaaatcttct tccaaagaag acttccatag ggtactgtta cagtaaccca gacaggagat 1080
gttaaggtct gaacctgggt attagtagtt agggaggaaa taaaattgag aaatattaca 1140
ctatgtaatt agagggcaca ccaaatggtt gagtgggagg tgtcaaagag aggtggatca 1200
gagttgtctt agttcagcta ctataacaaa tttccaaaga ctgaatggct taaaaaataa 1260
tttatgtctc acaattctgg aggacaggaa gtccaaggtc aaggctccag cagatttggt 1320
ctcctgtgag ggcctgcttc ctggtttgca aattgttttg tggctatctt ctcattgtat 1380
cttcacatag tggagggcag acagagagat ctcctgccac cttctctttt taaagggtac 1440
taatcccatt atgaggtccc cactgtcatg accacatcta acgctaattg cttatcaaag 1500
gccctacctt caaacaccat tatattgggg gttaggattt caacatatca gtttggagaa 1560
gacacaaata tttcgtgcat aacaagggac aattttcatg tatgtacaaa ggtcttcctt 1620
ggtaagacct ttcctgacca ctccactaaa actacaaatc atccttacca gcatccccta 1680
tcccttctct tccatctttc tctagtgctt atataatttc attattagct atctgtcttc 1740
actacaatat gtgagattct ttatggcagg gattttgtct cttttgttca ctgctgcatc 1800
acaatacctg cagcagtgcc tggcacctac tatgtactca ataagtatct gctcagtgaa 1860
tgaatgcctg atggtggtgc tgagaaaaac tgagaaaaaa atgcaggaag aagagcaagt 1920
ttagagaaaa tgatgctggg ttcacttttg cactttcttt agcactccag ggaaaaataa 1980
agctatgcag agactcagaa tgttggatat gacagaggcc ctagagacca tttgttttag 2040
tccatttatg ttgctataaa ggaatacctg aggctgggta atttataaa 2089
<210> 2
<211> 21
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 2
ccuacuaugu acucaauaag u 21
<210> 3
<211> 21
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 3
uuauugagua cauaguaggu g 21
<210> 4
<211> 21
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 4
caguggaagu gauuacuaag a 21
<210> 5
<211> 21
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 5
uuaguaauca cuuccacugg a 21
<210> 6
<211> 21
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 6
gcaccuacua uguacucaau a 21
<210> 7
<211> 21
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 7
uugaguacau aguaggugcc a 21
<210> 8
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 8
agaaccacag acaagggcac 20
<210> 9
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 9
atctccctgt tcatgcctgc 20
<210> 10
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 10
tctctgctcc tcctgttcga 20
<210> 11
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 11
gcgcccaata cgaccaaatc 20

Claims (7)

1.抑制 LOC107985830功能性表达的干扰RNA在制备牙髓干细胞成骨转化促进剂中的用途。
2.根据权利要求1所述的用途,其特征在于,所述LOC107985830的转录本序列为XR_001739224.1。
3.根据权利要求1所述的用途,其特征在于,所述干扰RNA选自LOC107985830的shRNA或siRNA。
4.根据权利要求1所述的用途,其特征在于,所述干扰RNA为LOC107985830的siRNA,所述siRNA的正义链为SEQ ID NO.4所示,所述siRNA的反义链为SEQ ID NO.5所述。
5. 一种促进牙髓干细胞成骨转化的促进剂,其特征在于,所述促进剂为抑制LOC107985830功能性表达的抑制剂,所述抑制剂为siRNA,所述siRNA的正义链为SEQ IDNO.4所示,所述siRNA的反义链为SEQ ID NO.5所示。
6.一种LOC107985830的基因抑制剂,其特征在于,所述抑制剂为LOC107985830的siRNA,所述siRNA的正义链为SEQ ID NO.4所示,所示siRNA的反义链为SEQ ID NO.5所示,所述siRNA能够促进牙髓干细胞的成骨转化。
7.一种长链非编码RNA,其特征在于,所述长链非编码RNA为LOC107985830,所述LOC107985830的转录本序列为XR_001739224.1,所述LOC107985830的抑制剂能够促进牙髓干细胞的成骨转化。
CN202011121438.7A 2020-10-20 2020-10-20 一种能够促进牙髓干细胞成骨转化的干扰rna及其应用 Active CN112239744B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011121438.7A CN112239744B (zh) 2020-10-20 2020-10-20 一种能够促进牙髓干细胞成骨转化的干扰rna及其应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011121438.7A CN112239744B (zh) 2020-10-20 2020-10-20 一种能够促进牙髓干细胞成骨转化的干扰rna及其应用

Publications (2)

Publication Number Publication Date
CN112239744A true CN112239744A (zh) 2021-01-19
CN112239744B CN112239744B (zh) 2021-08-03

Family

ID=74169103

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011121438.7A Active CN112239744B (zh) 2020-10-20 2020-10-20 一种能够促进牙髓干细胞成骨转化的干扰rna及其应用

Country Status (1)

Country Link
CN (1) CN112239744B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114107184A (zh) * 2021-11-26 2022-03-01 山东中医药大学第二附属医院 一种siRNA在牙髓干细胞成骨分化中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006010600A2 (en) * 2004-07-28 2006-02-02 Francesco Carinci Stem cells obtained from pulp of deciduous or permanent teeth and of dental germ, able to produce human bone tissue
CN107354127A (zh) * 2017-07-11 2017-11-17 山东大学 LncRNA‑TUG1在调控PDLSCs成骨分化及组织再生中的作用
CN111658775A (zh) * 2020-06-22 2020-09-15 青岛思拓新源细胞医学有限公司 长链非编码rna在干细胞成骨分化和成脂分化中的作用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006010600A2 (en) * 2004-07-28 2006-02-02 Francesco Carinci Stem cells obtained from pulp of deciduous or permanent teeth and of dental germ, able to produce human bone tissue
CN107354127A (zh) * 2017-07-11 2017-11-17 山东大学 LncRNA‑TUG1在调控PDLSCs成骨分化及组织再生中的作用
CN111658775A (zh) * 2020-06-22 2020-09-15 青岛思拓新源细胞医学有限公司 长链非编码rna在干细胞成骨分化和成脂分化中的作用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GENBANK: "Homo sapiens uncharacterized LOC107985830 (LOC107985830), ncRNA", 《GENBANK》 *
ZHONGJUN LIU等: "Differential expression of lncRNA/miRNA/mRNA and their related functional networks during the osteogenic/odontogenic differentiation of dental pulp stem cells", 《JOURNAL OF CELLULAR PHYSIOLOGY》 *
任春梅等: "非编码RNAs在人牙髓干细胞中的调控作用及机制", 《中国组织工程研究》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114107184A (zh) * 2021-11-26 2022-03-01 山东中医药大学第二附属医院 一种siRNA在牙髓干细胞成骨分化中的应用

Also Published As

Publication number Publication date
CN112239744B (zh) 2021-08-03

Similar Documents

Publication Publication Date Title
CN111658775B (zh) 长链非编码rna在干细胞成骨分化和成脂分化中的作用
CN110241196B (zh) circRNA PRKD3在牙周膜干细胞成骨分化中的应用
CN116064386A (zh) 永生化干细胞及其制作方法
CN112239744B (zh) 一种能够促进牙髓干细胞成骨转化的干扰rna及其应用
CN111304200B (zh) 一种调控高脂血症大鼠种植体周围骨整合的ceRNA调控网络及其应用
CN111500578A (zh) 调控ADSCs成骨分化及组织再生Circ RNA-FTO及其应用
CN104726500B (zh) MicroRNA26b‑3p抑制剂在制备人脐带来源间充质干细胞中的应用
CN116426469B (zh) LAP2α在间充质干细胞成脂向分化中的应用
CN104667294B (zh) miR‑216在制备促进成骨分化的药物中的用途
CN113413489B (zh) 一种含有Let-7a的牙周缺损修复系统
CN108676874B (zh) 循环外泌体长链非编码rna-tc0101441作为诊断子宫内膜异位症的标记物用途
CN114292850B (zh) 一种与山羊成肌细胞增殖和分化相关的circRNA及其应用
CN110408673A (zh) 研究Hsa_circ_0111659在WJ-MSCs修复ESC中的作用机制的方法
CN113430171B (zh) 一种转染miRNA的细胞膜片及其应用
CN111690603B (zh) 一种促进牙髓干细胞增殖和迁移的生物制剂
CN111154873B (zh) 一种三阴性乳腺癌细胞迁移和侵袭能力检测分子标志物及其应用
CN110664993B (zh) 纤维蛋白原γ链在牙齿再生领域的新用途及其试剂盒
CN110669763B (zh) 一种用于骨缺损修复的MSCs支架及其制备
CN113151267B (zh) 一种用于降低脐血间充质干细胞氧化应激凋亡的基因抑制剂
CN111214492A (zh) 多能干细胞外泌体在制备改善BMSCs增殖及成骨分化能力药物上的用途
CN106497871A (zh) 一种提高人羊膜间充质干细胞成骨分化效率的方法及应用
CN113350368B (zh) 一种基因抑制剂在制备表皮干细胞迁移药物制剂中的应用
CN110257522A (zh) 与乳腺癌诊疗相关的基因hsa_circ_0045881及其应用
CN109679952A (zh) 一种抗PRRSV感染的猪源miR-c89及其应用
CN113549593B (zh) 一种促进表皮干细胞增殖的药物制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20210714

Address after: 266000 Liaoyang West Road, Qingdao, Shandong 217

Applicant after: QINGDAO CITY WOMEN AND CHILDREN'S HOSPITAL (QINGDAO MATERNAL AND CHILD HEALTH HOSPITAL, QINGDAO DISABLED CHILDREN MEDICAL REHABILITATION CENTER, QINGDAO NEWBORN DISEASE SCREENING CENTER)

Applicant after: Qingdao cels Stem Cell Bank Co.,Ltd.

Address before: 266000 Liaoyang West Road, Qingdao, Shandong 217

Applicant before: QINGDAO CITY WOMEN AND CHILDREN'S HOSPITAL (QINGDAO MATERNAL AND CHILD HEALTH HOSPITAL, QINGDAO DISABLED CHILDREN MEDICAL REHABILITATION CENTER, QINGDAO NEWBORN DISEASE SCREENING CENTER)

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20220512

Address after: 266000 Liaoyang West Road, Qingdao, Shandong 217

Patentee after: QINGDAO WOMEN AND CHILDREN'S Hospital

Address before: 266000 Liaoyang West Road, Qingdao, Shandong 217

Patentee before: QINGDAO CITY WOMEN AND CHILDREN'S HOSPITAL (QINGDAO MATERNAL AND CHILD HEALTH HOSPITAL, QINGDAO DISABLED CHILDREN MEDICAL REHABILITATION CENTER, QINGDAO NEWBORN DISEASE SCREENING CENTER)

Patentee before: Qingdao cels Stem Cell Bank Co.,Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20230619

Address after: 266000 Liaoyang West Road, Qingdao, Shandong 217

Patentee after: QINGDAO CITY WOMEN AND CHILDREN'S HOSPITAL (QINGDAO MATERNAL AND CHILD HEALTH HOSPITAL, QINGDAO DISABLED CHILDREN MEDICAL REHABILITATION CENTER, QINGDAO NEWBORN DISEASE SCREENING CENTER)

Patentee after: Qingdao Situo Xinyuan Cell Medicine Co.,Ltd.

Address before: 266000 Liaoyang West Road, Qingdao, Shandong 217

Patentee before: QINGDAO CITY WOMEN AND CHILDREN'S HOSPITAL (QINGDAO MATERNAL AND CHILD HEALTH HOSPITAL, QINGDAO DISABLED CHILDREN MEDICAL REHABILITATION CENTER, QINGDAO NEWBORN DISEASE SCREENING CENTER)

Patentee before: Qingdao cels Stem Cell Bank Co.,Ltd.

TR01 Transfer of patent right